Children with immunoglobulin A nephropathy (IgAN) who achieved sustained remission of proteinuria for more than 90 days had significantly better kidney function 4 and 5 years later, according to new ...

The FDA granted final approval to OMCAZIO, a new cabozantinib capsule formulation for certain patients with kidney, liver and ...

SAN JOSE, CA AND TAIPEI, TW / ACCESS Newswire / September 11, 2026 / Handa Pharmaceuticals, Inc. ("Handa" or the "Company") (TSE:6620) announced that the U.S. Food and Drug Administration ("FDA") has ...

Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...

OMCAZIO approved for administration without regard to food, removing strict fasting requirements for cabozantinib patients SAN JOSE, CA AND TAIPEI, TW / ACCESS Newswire / September 11, 2026 / Handa Ph ...

Most foamy urine is nothing to worry about but not all of it A urologist explains when its harmless when its not and what ...

Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment ...

The "Focal Segmental Glomerulosclerosis - Market Insight, Epidemiology, Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The report provides an in-depth assessment of FSGS ...

First two patients dosed in the EXACT study Topline data from the initial 16-week placebo-controlled portion of the study expected mid-2027; final readout expected ...

The patient's phenotype, rather than the variant of uncertain significance, supported withholding immunosuppression and using supportive therapy.

Finerenone has shown positive therapeutic effects in diabetic kidney disease, but its role in hereditary podocytopathies such as hereditary FSGS has not been fully explored.

The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...